Citas bibligráficas
Perez, N., (2024). Proyecto de implementación de guía para el diseño de laboratorios farmacéuticos enfocado a la fase de diseño de formas no estériles [Universidad Peruana Cayetano Heredia]. https://hdl.handle.net/20.500.12866/15551
Perez, N., Proyecto de implementación de guía para el diseño de laboratorios farmacéuticos enfocado a la fase de diseño de formas no estériles []. PE: Universidad Peruana Cayetano Heredia; 2024. https://hdl.handle.net/20.500.12866/15551
@misc{renati/911393,
title = "Proyecto de implementación de guía para el diseño de laboratorios farmacéuticos enfocado a la fase de diseño de formas no estériles",
author = "Perez Moron, Nestor Alonso",
publisher = "Universidad Peruana Cayetano Heredia",
year = "2024"
}
The implementation of a new laboratory entails a series of activities that, if not clear, generate delays and economic losses affecting the investment made by investors. In the pharmaceutical industry, there are workflows that, if not followed, prevent the continuation of subsequent work due to being prerequisites. The present work seeks to elucidate the flows that a new pharmaceutical laboratory needs to follow in order to optimize the timings in its implementation. This roadmap for new laboratories is developed thanks to personal experience in laboratory implementation and experience in the sector to obtain Good Manufacturing Practices (GMP) for the manufacturing of sterile and non-sterile product lines. I was given the experience from the area of Validations and Qualifications, and the challenge was to complete all validations and qualifications to defend in the DIGEMID audit, for which the technical concepts of validations and the critical and analytical thinking that the University is responsible for developing in all students were used. Carrying out the implementation of a laboratory required the development of a work plan to achieve the objectives set for the audit. These pieces of knowledge are what are sought to be captured in the following work for the opening of pharmaceutical establishments dedicated to the manufacture of nonsterile pharmaceutical products, avoiding deviations and non-conformities that cause cost overruns and delays.
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons